Entry into a Material Definitive Agreement

On July 14, 2022 HTG Molecular Diagnostics, Inc. (the "Company") reported that entered into an amendment (the "Amendment") to its Loan and Security Agreement, dated June 24, 2020, by and between the Company and Silicon Valley Bank (the "Loan Agreement") (Filing, 8-K, HTG Molecular Diagnostics, JUL 14, 2022, View Source [SID1234616729]). Under the Loan Agreement, Silicon Valley Bank provided the Company with a $10.0 million principal amount secured term loan (the "Term Loan"), of which $7.5 million remained outstanding as of June 30, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pursuant to the Amendment, the Company and Silicon Valley Bank agreed to remove the financial covenant under the Loan Agreement that had required the Company to maintain unrestricted cash, including short term investments available-for-sale, of not less than the greater of (i) $12.5 million and (ii) an amount equal to six times the amount of the Company’s average monthly Cash Burn (as defined in the Loan Agreement) over the trailing three months. In exchange for this accommodation, the Company prepaid $2.5 million of outstanding principal under the Term Loan (the "Prepayment"). Silicon Valley Bank waived the prepayment fee that otherwise would have applied to the Prepayment. The remaining outstanding principal amount under the Term Loan will continue to be paid in equal monthly payments of principal and interest through the maturity date of December 1, 2023.

West to Host Second-Quarter 2022 Conference Call

On July 14, 2022 West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, reported that it will release second-quarter 2022 financial results before the market opens on Thursday, July 28, 2022, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time (Press release, West Pharmaceutical Services, JUL 14, 2022, View Source [SID1234616708]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live audio-only webcast will be made available via the Company’s Investor Relations website https://bit.ly/3cgSM9S or by clicking here.

To participate in the conference call by asking questions to Management, please register in advance at https://bit.ly/3z4iU0g. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that will be used to access the call.

Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the presentation, select "Presentations" in the "Investors" section of the Company’s website.

A replay of the conference call and webcast will be available on the Company’s website for 30 days.

Labcorp to Announce Second Quarter Financial Results on July 28, 2022

On July 14, 2022 Labcorp (NYSE: LH), a leading global life sciences company, reported that it will release its financial results for the second quarter of 2022 before the market opens on Thursday, July 28, 2022 (Press release, LabCorp, JUL 14, 2022, View Source [SID1234616699]). The company will host a conference call and webcast beginning at 9 a.m. EDT that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can access the conference call by dialing 1-800-715-9871 within the U.S. and Canada, or 1-646-307-1963 internationally, using the conference ID 4124787. In addition, a real-time webcast of the conference call will be available on the Labcorp Investor Relations website.

An audio replay of the conference call will be available from 2 p.m. EDT on July 28, 2022, until 11:30 p.m. EDT on August 11, 2022, by dialing 1-800-770-2030 within the U.S. and Canada, or 1-609-800-9909 internationally, using the conference ID 4124787. The webcast of the conference call will be archived and accessible through July 14, 2023, on the Labcorp Investor Relations website.

Labcorp Declares Quarterly Dividend

On July 14, 2022 Labcorp (NYSE: LH) (the Company), a leading global life sciences company, reported that its Board of Directors (the Board) has declared a cash dividend of $0.72 per share of common stock (Press release, LabCorp, JUL 14, 2022, View Source [SID1234616698]). The dividend will be payable on September 9, 2022, to stockholders of record as of the close of business on August 18, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


GenScript ProBio and DAAN Bio Therapeutics, Sign a Strategic Cooperation MOU for the Discovery and Development of Novel Drugs

On July 14, 2022 GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and DAAN Bio Therapeutics (Byoung Chul Cho, Co-Founder & CEO), an innovative new drug developer such as antibody treatments and cell therapy drugs, reported that they had entered into a strategic cooperation MOU concerning the development for innovation drug discovery & development (Press release, GenScript ProBio, JUL 14, 2022, View Source [SID1234616695]). GenScript ProBio and DAAN have agreed to strengthen their cooperation in the cell and gene therapy (CGT) and biologics field through this MOU.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through this agreement, both companies will strategically cooperate in the overall development process, such as discovery, manufacturing, and clinical trials of antibody and cell treatments, and related research and service projects.

DAAN Bio Therapeutics has conducted single cell transcriptomic and proteomic biomarker analysis through its own analysis platform using tissues secured from solid cancer patients along with DAAN Cancer Research Institute and Yonsei New Il Han Institute for Integrative Cancer Research.

Accordingly, DAAN Bio Therapeutics signed a contract manufacturing organization (CMO) service through GenScript ProBio to develop antibodies that specifically bind to the discovered target material, and established its own bispecific antibody production pipeline using antibodies derived through GMP production.

Brian H. Min, CEO of GenScript ProBio, said "I hope this strategic partnership with DAAN Bio Therapeutics will be of great support as a global partner in accelerating the development of DAAN’s antibody and cell therapy through the GenScript ProBio’s one-stop CDMO service platform. "

Byoung Chul Cho, Co-Founder & CEO of DAAN Bio Therapeutics, said "This strategic cooperation will be an opportunity to revitalize the development of antibody and cell therapy that control unique cancer treatment targets secured by DAAN Bio Therapeutics using GenScript ProBio’s qualified and competitive technologies."

Through this strategic partnership, both GenScript ProBio and DAAN Bio Therapeutics will continue their cooperation more closely with each other to develop subsequent pipelines of DAAN Bio Therapeutics, such as antibody drug and cell therapy.